HOME >> MEDICINE >> NEWS
Long-term benefits found in two drugs for Parkinson's

Two drugs used to treat hallucinations in patients with Parkinsons disease (PD) can not only reduce hallucinations, but may also lead to long-term benefits in these patients, according to a group of Emory University researchers. The long-term benefits may include reduced mortality and a reduced risk of nursing home placement. The drugs studied were the atypical antipsychotics quetiapine (trade name Seroquel) and clozapine (trade name Clozaril).

Jorge Juncos, M.D., associate professor of neurology, Emory University School of Medicine, and colleagues will present their findings at the American Academy of Neurology 54th Annual Meeting in Denver, Colo., on April 18. The research will also appear as an abstract in the April issue of the journal, Neurology.

"Drug-induced psychotic symptoms, such as visual hallucinations, are seen in a significant number of patients with advanced PD," says Dr. Juncos. "Approximately 15 to 20 percent of PD patients may experience these hallucinations over time. They are due to a interaction between the progression of the illness and the drugs used to treat its symptoms," Dr. Juncos explains.

The Emory researchers conducted a retrospective chart review between 1996 and 2001 in 27 patients with advanced PD (mean duration of illness of 13 years, plus or minus six years). Hallucinations had been treated for approximately 36 months using quetiapine in 23 patients and clozapine in four patients.

"We compared the antipsychotic efficacy, mortality and risk of nursing home placement to published historical data (Goetz & Stebbins, Neurology 1996) in similarly affected patients treated with low doses of typical anti-psychotics before 1996," Dr. Juncos says.

Based on clinical exams or caregiver reports, Emory researchers found hallucinations in these patients were reduced by almost half (from 100 to 59 percent) while patients were on one of the study medications. Symptoms of agitation were also re
'"/>

Contact: Janet Christenbury
jmchris@emory.edu
404-727-8599
Emory University Health Sciences Center
18-Apr-2002


Page: 1 2

Related medicine news :

1. Long-term high consumption of red and processed meat linked with increased risk for colon cancer
2. Long-term data show benefit of DETROL LA as first-line therapy for overactive bladder
3. Long-term benefits for newly diagnosed patients with CML receiving first-line therapy with imatinib
4. Long-term obesity linked to loss of brain tissue in women
5. Long-term study demonstrated ADDERALL XR is an effective option to treat adolescents with ADHA
6. Long-term study proves ADDERALL XR is a safe and effective option to treat adults with ADHD
7. Long-term use of antibiotics possibly linked with increased risk of breast cancer
8. Long-term follow-up of mortality in patients with community-acquired pneumonia
9. Long-term outcome of epilepsy surgery is favorable for many
10. Long-term ERT in postmenopausal women with Alzheimers may worsen memory
11. Long-term avoidance of milk in children results in poor bone health

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2017)... New York (PRWEB) , ... August 23, 2017 , ... ... intellectual and developmental disabilities (I/DD), has launched a groundbreaking LGBTQ community organization for people ... just the first organization of its kind in the state of New Jersey – ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... Jachimowicz ... California, office at 1530 The Alameda, Suite 115. The office is located between Schiele ... the contact information remains the same. Clients can still call the office at 408-246-5500. ...
(Date:8/23/2017)... Texas (PRWEB) , ... August 23, 2017 , ... This ... denied claims firms in Texas. Founded by Bill Voss, the firm grew quickly and ... decade and a half of helping clients get the money they deserve from their ...
(Date:8/23/2017)... ... 2017 , ... Loyale Healthcare today announced the ... joins other recent high-profile hires including Frank Massi, Chief Revenue Officer and Shirley ... helping physician practices and hospitals automate their clinical and financial processes to gain ...
(Date:8/23/2017)... ... 2017 , ... Drs. Steven White and Brad Haines are pleased to announce ... of this offer, valued at more than $300 per year, new patients can enjoy ... patients receive a complimentary professional whitening procedure. , Stained or yellowed tooth enamel ...
Breaking Medicine News(10 mins):
(Date:8/23/2017)... 23, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... health and big data solutions, announced today that ... with domestic and non-U.S. investors for the sale ... shares of the Company,s newly designated Series B ... Current shareholders accounted for 58% of the securities ...
(Date:8/23/2017)... -- Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing ... epilepsy, announced today that the U.S. Food and Drug ... the treatment of patients with Dravet Syndrome. Dravet Syndrome ... of the Food, Drug, and Cosmetic Act. ... of epilepsy, begins in the first year of life ...
(Date:8/18/2017)... , Aug. 18, 2017  Nortis today announced the awarding of a $688K ... for the third year of a Small Business Innovation ... Institute of Neurological Disorders and Stroke (NINDS).?  ... Nortis ParVivo Chip ... ...
Breaking Medicine Technology:
Cached News: